Literature DB >> 30742505

Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors Awareness, Education, and Literature Review.

Mario E Lacouture, David J Kopsky, Raphael Lilker, Fiona Damstra, Mecheline H M van der Linden, Azael Freites-Martinez, Mischa P M Nagel.   

Abstract

Cancer is one of the leading causes of mortality and morbidity worldwide. Recent improved therapies have resulted in more patients surviving cancer and living longer. Despite these advances, the majority of patients will develop adverse events from anticancer therapies. Foot alterations, including nail toxicities, hand-foot syndrome, edema, xerosis, hyperkeratosis, and neuropathy, are frequent among cancer patients. These untoward conditions may negatively impact quality of life, and in some cases may result in the interruption or discontinuation of cancer treatments. Appropriate prevention, diagnosis, and management of podiatric adverse events are essential to maintain foot function and health-related quality of life, both of which are critical for the care of cancer patients and survivors. This article shows results related to complaint and impact on quality of life of the Oncology Foot Care program and reviews publications specific to podiatric adverse events related to cancer treatments.

Entities:  

Mesh:

Year:  2018        PMID: 30742505      PMCID: PMC8108701          DOI: 10.7547/17-010

Source DB:  PubMed          Journal:  J Am Podiatr Med Assoc        ISSN: 1930-8264


  44 in total

Review 1.  Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome).

Authors:  D Lorusso; A Di Stefano; V Carone; A Fagotti; S Pisconti; G Scambia
Journal:  Ann Oncol       Date:  2007-01-17       Impact factor: 32.976

Review 2.  Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.

Authors:  James B Macdonald; Brooke Macdonald; Loren E Golitz; Patricia LoRusso; Aleksandar Sekulic
Journal:  J Am Acad Dermatol       Date:  2015-02       Impact factor: 11.527

Review 3.  Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity?

Authors:  Guido Cavaletti; Paola Alberti; Paola Marmiroli
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

Review 4.  Exercise intervention studies in patients with peripheral neuropathy: a systematic review.

Authors:  Fiona Streckmann; Eva M Zopf; Helmar C Lehmann; Kathrin May; Julia Rizza; Philipp Zimmer; Albert Gollhofer; Wilhelm Bloch; Freerk T Baumann
Journal:  Sports Med       Date:  2014-09       Impact factor: 11.136

5.  HFS-14, a specific quality of life scale developed for patients suffering from hand-foot syndrome.

Authors:  Vincent Sibaud; Florence Dalenc; Christine Chevreau; Henri Roché; Jean-Pierre Delord; Loïc Mourey; Jean-Louis Lacaze; Nora Rahhali; Charles Taïeb
Journal:  Oncologist       Date:  2011-09-30

Review 6.  The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis.

Authors:  Yevgeniy Balagula; Shenhong Wu; Xiao Su; Darren R Feldman; Mario E Lacouture
Journal:  Invest New Drugs       Date:  2011-03-11       Impact factor: 3.850

7.  Does footwear affect balance?: the views and experiences of people with diabetes and neuropathy who have fallen.

Authors:  Joanne S Paton; Anne Roberts; Graham K Bruce; Jon Marsden
Journal:  J Am Podiatr Med Assoc       Date:  2013 Nov-Dec

8.  Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy.

Authors:  E A Calhoun; E E Welshman; C-H Chang; J R Lurain; D A Fishman; T L Hunt; D Cella
Journal:  Int J Gynecol Cancer       Date:  2003 Nov-Dec       Impact factor: 3.437

9.  Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy.

Authors:  F Streckmann; S Kneis; J A Leifert; F T Baumann; M Kleber; G Ihorst; L Herich; V Grüssinger; A Gollhofer; H Bertz
Journal:  Ann Oncol       Date:  2014-02       Impact factor: 32.976

Review 10.  Chemotherapy induced peripheral neuropathic pain.

Authors:  Hue Jung Park
Journal:  Korean J Anesthesiol       Date:  2014-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.